source
- Novartis and Bristol Myers pause autoimmune CAR-T trials after safety concernsNovartis announced a temporary hold on its personalized CAR-T therapy rap-cel after three patients experienced immune effector cell-associated hemophagocytic syndrome, a rare and potentially life-t…
- Novartis and Bristol Myers pause multiple autoimmune CAR-T trials after serious immune adverse eventsNovartis and Bristol Myers Squibb announced a temporary halt to several CAR-T cell therapy trials targeting autoimmune diseases. The pause involves Novartis’s autologous CD19 CAR-T candidate rapca…